Lonza Pharma & Biotech
Due to the intrinsic enteric properties of Capsugel® Vcaps® Enteric, no coating step is needed. It means that this capsule is a ready-to-use solution that can help you in obtaining significant cost and time savings during pharmaceutical development or compounding.
Capsugel® Vcaps® Enteric Capsule is a fully compliant capsule technology that simplifies drug enteric delivery implementation from early-stage development to commercial manufacturing. The pharmaceutical grades of cellulosic derivatives used in Capsugel® Vcaps® Enteric capsules are approved and have extensive market precedence for use in providing enteric protection. They have been evaluated in-vitro and in-vivo across a number of compounds, which has proven full compliance with relevant European, Japanese and US Pharmacopeia monographs.
Capsugel® Vcaps® Enteric capsules can be utilized to greatly simplify and accelerate prototype development and rapid in-vivo testing of products requiring targeted delivery to the upper GI tract:
- Eliminate coating system preparation and application steps
- Rapid screening and optimization of enteric performance
- Remove dependency of enteric functionality with process variability
- Obviate need for process development of the enteric coating step, process scale-up and validation
Product Description
- Two-piece hard capsule
- Manufactured with pharmaceutical-grade cellulosic derivatives (HPMCAS, HPMC)
Contact Details:
Company name: Lonza Pharma & Biotech
Website: www.capsugel.com/biopharmaceutical-products/vcaps-enteric-capsules
E-mail: solutions.emea@lonza.com
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
The Role of Forced Degradation in Method Development, Manufacturability, and CMC Strategy
April 28th 2025Forced degradation studies are critical in biologics development, particularly for monoclonal antibodies (mAbs). These studies simulate long-term environmental stressors to uncover degradation pathways and ensure the stability of critical quality attributes (CQAs), aiding in robust chemistry, manufacturing, and controls (CMC) strategies and regulatory compliance.
